Results for tag: "Muraglitazar"

Muraglitazar is a class of gastrointestinal drugs used to treat type 2 diabetes. It is a dual-acting peroxisome proliferator-activated receptor (PPAR) agonist, meaning it works by activating two different PPAR receptors in the body. This dual-action helps to improve glycemic control and reduce the risk of cardiovascular events. Muraglitazar is typically prescribed in combination with other diabetes medications, such as metformin or sulfonylureas. It is also used to treat dyslipidemia, a condition characterized by high levels of cholesterol and triglycerides. Muraglitazar is available in both oral and injectable forms. The oral form is taken once daily, while the injectable form is administered once every two weeks. Common side effects of muraglitazar include nausea, diarrhea, and abdominal pain. The muraglitazar market is highly competitive, with several major pharmaceutical companies offering products. These include Merck & Co., Novartis, Sanofi, and Takeda Pharmaceuticals. Other companies, such as Eli Lilly and Boehringer Ingelheim, also offer muraglitazar products. Show Less Read more